GLP-1 receptor agonists like semaglutide and tirzepatide have transformed obesity medicine. Here’s the science behind why they work when so many other approaches haven’t.
For decades, the dominant narrative around weight loss was simple: eat less, move more. If that didn’t work, the assumption was that the patient wasn’t trying hard enough. GLP-1 receptor agonists have done more than help people lose weight — they’ve helped dismantle that narrative by demonstrating, in clinical trials involving tens of thousands of patients, that weight regulation is a biological process, not a character test.
What is GLP-1?
GLP-1 (glucagon-like peptide-1) is a hormone produced naturally in the gut in response to eating. It plays several roles in metabolism: it stimulates insulin secretion, suppresses glucagon (which raises blood sugar), slows gastric emptying, and — critically — signals the brain that you’ve eaten enough.
In people with obesity, this signaling system is often dysregulated. The brain’s appetite centers don’t receive adequate satiety signals, or they’ve been recalibrated to defend a higher body weight. GLP-1 receptor agonists work by mimicking and amplifying this natural hormone, restoring the signaling that should be telling the brain “enough.”
Semaglutide vs. Tirzepatide
Semaglutide (the active ingredient in Wegovy® for weight management and Ozempic® for diabetes) was the first GLP-1 agonist approved specifically for chronic weight management. In the STEP trials, patients on semaglutide lost an average of 15–17% of body weight over 68 weeks — results that had never been seen with any non-surgical intervention.
Tirzepatide (Zepbound®) is a newer dual agonist that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The SURMOUNT trials showed average weight loss of 20–22% — approaching the results seen with bariatric surgery. The dual mechanism appears to produce stronger appetite suppression and metabolic effects than GLP-1 alone.
Average weight loss with tirzepatide in clinical trials: 20–22% of body weight over 72 weeks. For a 250-pound person, that’s 50–55 pounds.
Why the Side Effects Happen
The most common side effects of GLP-1 medications — nausea, vomiting, constipation, and other GI symptoms — are a direct consequence of how they work. Slowing gastric emptying means food stays in the stomach longer, which causes nausea, particularly early in treatment and during dose escalation.
These symptoms are typically most pronounced in the first 4–8 weeks and improve significantly as the body adapts. Dose escalation protocols are designed specifically to minimize side effects by starting low and increasing gradually. Most patients who stay with the medication through the initial adjustment period find the side effects become manageable or resolve entirely.
What This Means for Patients
The most important thing to understand about GLP-1 medications is that they are treating a biological condition, not compensating for a behavioral failure. When the medication works — and for most patients it does — it’s because it’s correcting a dysregulated system, not overriding willpower.
This also explains why weight regain is common after stopping the medication. The underlying biology hasn’t changed; the medication was managing it. This is why at SCAPS, we pair medication with a comprehensive education curriculum — because the behavioral and nutritional habits patients build during treatment are what determine long-term outcomes after medication changes.
“Obesity is a chronic disease. We don’t expect patients with hypertension to stop their medication after 12 weeks. We should apply the same thinking to obesity treatment.”
— Dr. Margaret Calloway, SCAPS Medical Director